CB-5083

/static/temp/default.svg

Search structure


Synonyms	Cb 5083 Cb-5083
Status
Molecule Category	UNKNOWN
UNII	591IV6UL6J


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	RDALZZCKQFLGJP-UHFFFAOYSA-N
Smiles	Cc1cc2c(C(N)=O)cccc2n1-c1nc2c(c(NCc3ccccc3)n1)COCC2
InChI	InChI=1S/C24H23N5O2/c1-15-12-18-17(22(25)30)8-5-9-21(18)29(15)24-27-20-10-11-31-14-19(20)23(28-24)26-13-16-6-3-2-4-7-16/h2-9,12H,10-11,13-14H2,1H3,(H2,25,30)(H,26,27,28)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C24H23N5O2
Molecular Weight	413.48
AlogP	3.51
Hydrogen Bond Acceptor	6.0
Hydrogen Bond Donor	2.0
Number of Rotational Bond	5.0
Polar Surface Area	95.06
Molecular species	NEUTRAL
Aromatic Rings	4.0
Heavy Atoms	31.0

Assay Description	Organism	Bioactivity	Reference
Inhibition of human p97 ATPase incubated for 15 mins by ADP Glo luminescence assay	Homo sapiens	11.0 nM
Cytotoxicity against human A549 cells assessed as cell viability after 72 hrs by Celltiter-Glo assay	Homo sapiens	680.0 nM
Inhibition of p97 ATPase in human A549 cells assessed as accumulation of K48 poly-ubiquitinated proteins incubated for 6 hrs by immunofluorescence assay	Homo sapiens	680.0 nM
Inhibition of p97 ATPase in human A549 cells assessed as reduction in p62 protein incubated for 6 hrs by immunofluorescence assay	Homo sapiens	490.0 nM
Inhibition of human p97 ATPase domain1 at 10 uM incubated for 15 mins by ADP Glo luminescence assay	Homo sapiens	-38.9 %
Inhibition of human p97 ATPase domain2 at 10 uM incubated for 15 mins by ADP Glo luminescence assay	Homo sapiens	96.5 %
Inhibition of DNAPK (unknown origin)	Homo sapiens	500.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	6.99 %
Inhibition of human p97 using ATP as substrate after 60 mins by ADP-Glo assay	Homo sapiens	27.0 nM
Inhibition of His-tagged p97 (unknown origin) in presence of ATP and PNP by UV-transparent microplate assay	Homo sapiens	26.1 nM
Antiproliferative activity against human MIAPaCa2 cells	Homo sapiens	146.0 nM
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	-35.94 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	15.67 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.25 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.23 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.23 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	-0.25 %
Inhibition of p97 (unknown origin) incubated for 60 mins by ADP-Glo assay	Homo sapiens	44.0 nM
Cytotoxicity against human RPMI-8226 cells assessed as reduction in cell viability incubated for 72 hrs by CCK8 assay	Homo sapiens	800.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL3747513
FDA SRS	591IV6UL6J
PDB	JDP
PubChem	73051434
SureChEMBL	SCHEMBL15421452
ZINC	ZINC000208076131

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).